Cenegermin-Bkbj
Brand name: Oxervate
Rank #126 of 500 drugs by total cost
$133.5M
Total Cost
3,601
Total Claims
$133.5M
Total Cost
175
Prescribers
$37K
Cost per Claim
177
Beneficiaries
3,602
30-Day Fills
$763K
Avg Cost/Provider
21
Avg Claims/Provider
About Cenegermin-Bkbj
Cenegermin-Bkbj (sold as Oxervate) was prescribed 3,601 times by 175 Medicare Part D providers in 2023, costing the program $133.5M. At $37K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 123 | Dasatinib (Sprycel) | $136.8M | 10,389 |
| 124 | Oxycodone Hcl/Acetaminophen (Oxycodone-Acetaminophen) | $136.4M | 3,487,099 |
| 125 | Buprenorphine Hcl/Naloxone Hcl (Buprenorphine-Naloxone) | $135.8M | 696,008 |
| 126 | Cenegermin-Bkbj (Oxervate) | $133.5M | 3,601 |
| 127 | Teriflunomide (Aubagio) | $131.9M | 18,010 |
| 128 | Umeclidinium Bromide (Incruse Ellipta) | $131.6M | 290,677 |
| 129 | Tiotropium Br/Olodaterol Hcl (Stiolto Respimat) | $130.3M | 201,233 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology